SEC Comment Letter for PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Sep 17, 2012

PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Sept. 17, 2012 · CIK: 0001095981 · Accession: 0000000000-12-050626

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

September 17, 2012

Author

/s/ Brian Cascio

Form

UPLOAD

Company

PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)

Letter

September 17, 2012 Via E -mail Mark Saad Chief Financial Officer Cytori Therapeutics, Inc. 3020 Callan Road San Diego, CA 92121

Re: Cytori Therapeutics, Inc. Form 10 -K for the Fiscal Year Ended December 31, 2011 Filed March 13, 2012 File No. 001 -34375

Dear Mr. Saad :

We have completed our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing s and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,
/s/ Brian Cascio

Show Raw Text

September 17, 2012

Via E -mail
Mark Saad
Chief Financial Officer
Cytori Therapeutics, Inc.
3020 Callan Road
San Diego, CA 92121

Re: Cytori Therapeutics, Inc.
Form 10 -K for the Fiscal  Year Ended December 31, 2011
Filed March 13, 2012
File No. 001 -34375

Dear Mr. Saad :

We have completed our review of your filings .  We remind you that our comments or
changes to disclosure in response to our comments do not foreclose the Commission from taking
any action with respect to the company or the filing s and the company may not assert staff
comments as a defense in any proceeding initiated by the Commission or any person under the
federal securities laws of the United States.  We urge all persons  who are responsible for the
accuracy and adequacy of the disclosure in the filing s to be certain that the filing s include  the
information the Securities Exchange Act of 1934 and all applicable rules require.

        Sincerely,

        /s/ Brian Cascio

        Brian Cascio
        Accounting Branch Chief

SecProbe.io